Business
PRTC's Seaport Appoints Global Pharma Exec to BOD
PRTC's Seaport Appoints Global Pharma Exec to BOD.
About this update from Puretech Health Plc
[{"type":"text","content":"\n\n13 August 2024\nPureTech Health plc\n \nPureTech Founded Entity Seaport Therapeutics Appoints David Wheadon, M.D., to its Board of Directors\n \nProminent pharmaceutical leader from AstraZeneca, Abbott, GlaxoSmithKline and Eli Lilly, brings extensive regulatory affairs and clinical development expertise to Seaport Board\n \nPureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (\"PureTech\" or the \"Company\"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of David Wheadon, M.D., to its Board of Directors. Dr. Wheadon is a physician and psychiatrist with more than three decades of experience in regulatory affairs, clinical strategy, and global health policy at multinational companies across the pharmaceutical industry.\n \nThe full text of the announcement from Seaport is as follows:\n \nSeaport Therapeutics Appoints David Wheadon, M.D., to its Board of Directors\n \nProminent pharmaceutical leader from AstraZeneca, Abbott, GlaxoSmithKline and Eli Lilly, brings extensive regulatory affairs and clinical development expertise to Seaport Board\n \nBOSTON, August 13, 2024 - Seaport Therapeutics, a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of David Wheadon, M.D., to its Board of Directors. Dr. Wheadon is a physician and psychiatrist with more than three decades of experience in regulatory affairs, clinical strategy, and global health policy at multinational companies across the pharmaceutical industry.\n \n\"It is our pleasure to welcome David Wheadon to our Board of Directors,\" said Daphne Zohar, Founder and Chief Executive Officer at Seaport. \"David brings extensive regulatory expertise, and a successful background in the development and approval of several important neuropsychiatric medicines which will benefit Seaport as we advance our clinical-stage pipeline of therapeutics for the treatment of depression, anxiety and other neuropsychiatric disorders.\"\n \nDr. Wheadon is a distinguished pharmaceutical leader who most recently served as Senior Vice President, Global Regulatory Affairs...